Caplyta approved for relapse in schizophrenia

The FDA has approved Johnson & Johnson’s supplemental new drug application for Caplyta among patients with schizophrenia at risk for relapse, according to a press release from the company.
Noting that schizophrenia affects approximately 2.8 million adults in the United States, with a total cost of $366.8 billion in 2024, Johnson & Johnson said approximately 40% of patients do not receive adequate care.
Relapse remains “one of the most critical challenges” for patients with schizophrenia, Leighann Forbes, MS, PhD, vice president, U.S. neuroscience medical affairs, Johnson & Johnson,








